Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Released On
July 29, 2021

Expires On
July 29, 2022

Media Type

Completion Time
90 minutes


Autoimmune Disorders, Rare Diseases

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate.

Activity Overview

Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment options has hindered management of CAD. However, the treatment landscape is shifting as novel therapies are developed based on improved understanding of the role of the complement system in the pathogenesis of CAD. Health care professionals require a strong foundation of knowledge in the efficacy, safety, and role of both available and emerging therapies for CAD to improve the outcomes in this patient population.

This program features experts presenting important topics on CAD, including the burden of disease and the impact of CAD on patient quality of life, as well as the role of the complement system in CAD. The program also includes expert review of current and emerging data surrounding strategies for rapid and accurate diagnosis, current management approaches and the potential of emerging treatments.

This educational activity is an archive of the live virtual presentation held on June 10, 2021.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the clinical burden of cold agglutinin disease.
  • Explain how the complement system is implicated in the onset of cold agglutinin disease.
  • Apply diagnostic criteria to facilitate an accurate and timely diagnosis of cold agglutinin disease.
  • Identify complement-mediated therapies for the treatment of cold agglutinin disease based on current and emerging evidence.




Alexander Röth, MD

Department of Hematology and
Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
University Duisburg-Essen
Essen, Germany


Sigbjørn Berentsen, MD, PhD

Consultant Hematologist and Senior Researcher
Department of Research and Innovation
Helse Fonna HF, Haugesund Hospital
Haugesund, Norway


Wilma Barcellini, MD

Director, UOS Physiopathology of Anemias
UO Hematology – Granelli Pavilion
IRCCS Ca’ Granda Foundation
Maggiore Policlinico Hospital
Milan, Italy


Catherine M. Broome, MD

Associate Professor of Medicine
MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center
Washington, DC

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest


Alexander Röth, MD

  • Grant Research Support: Hoffmann-La Roche
  • Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals, BioCryst Pharmaceuticals, Novartis Pharmaceuticals Corporation, Hoffmann-La Roche, Sanofi.



Sigbjørn Berentsen, MD, PhD

  • Consultant: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Momenta Pharmaceuticals, Sobi
  • Other: Lecture honoraria: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Janssen-Cilag



Wilma Barcellini, MD

  • Consultant: Apellis Pharmaceuticals, Incyte Corporation, Sanofi



Catherine M. Broome, MD

  • Other: Advisory Board


The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.